Correction to: RGD4C peptide mediates anti-p21Ras scFv entry into tumor cells and produces an inhibitory effect on the human colon cancer cell line SW480

Chen-Chen Huang,Fang-Rui Liu,Qiang Feng,Xin-Yan Pan,Shu-Ling Song,Ju-Lun Yang

DOI: https://doi.org/10.1186/s12885-021-08120-z

IF: 4.638

2021-04-07

BMC Cancer

Abstract:An amendment to this paper has been published and can be accessed via the original article.

oncology

What problem does this paper attempt to address?

RGD4C peptide mediates anti-p21Ras scFv entry into tumor cells and produces an inhibitory effect on the human colon cancer cell line SW480

Chen-Chen Huang,Fang-Rui Liu,Qiang Feng,Xin-Yan Pan,Shu-Ling Song,Ju-Lun Yang

DOI: https://doi.org/10.1186/s12885-021-08056-4

IF: 4.638

2021-03-25

BMC Cancer

Abstract:Abstract Background We prepared an anti-p21Ras scFv which could specifically bind with mutant and wild-type p21Ras. However, it cannot penetrate the cell membrane, which prevents it from binding to p21Ras in the cytoplasm. Here, the RGD4C peptide was used to mediate the scFv penetration into tumor cells and produce antitumor effects. Methods RGD4C-EGFP and RGD4C-p21Ras-scFv recombinant expression plasmids were constructed to express fusion proteins in E. coli , then the fusion proteins were purified with HisPur Ni-NTA. RGD4C-EGFP was used as reporter to test the factors affecting RGD4C penetration into tumor cell. The immunoreactivity of RGD4C-p21Ras-scFv toward p21Ras was identified by ELISA and western blotting. The ability of RGD4C-p21Ras-scFv to penetrate SW480 cells and colocalization with Ras protein was detected by immunocytochemistry and immunofluorescence. The antitumor activity of the RGD4C-p21Ras-scFv was assessed with the MTT, TUNEL, colony formation and cell migration assays. Chloroquine (CQ) was used an endosomal escape enhancing agent to enhance endosomal escape of RGD4C-scFv. Results RGD4C-p21Ras-scFv fusion protein were successfully expressed and purified. We found that the RGD4C fusion protein could penetrate into tumor cells, but the tumor cell entry of was time and concentration dependent. Endocytosis inhibitors and a low temperature inhibited RGD4C fusion protein endocytosis into cells. The change of the cell membrane potential did not affect penetrability. RGD4C-p21Ras-scFv could penetrate SW480 cells, effectively inhibit the growth, proliferation and migration of SW480 cells and promote this cells apoptosis. In addition, chloroquine (CQ) could increase endosomal escape and improve antitumor activity of RGD4C-scFv in SW480 cells. Conclusion The RGD4C peptide can mediate anti-p21Ras scFv entry into SW480 cells and produce an inhibitory effect, which indicates that RGD4C-p21Ras-scFv may be a potential therapeutic antibody for the treatment of ras-driven cancers.

oncology
Correction to: Circ-ASH2L promotes tumor progression by sponging miR-34a to regulate Notch1 in pancreatic ductal adenocarcinoma

Yan Chen,Zhonghu Li,Mengyun Zhang,Bo Wang,Jiaxin Ye,Yang Zhang,Di Tang,Dandan Ma,Weidong Jin,Xiaowu Li,Shuguang Wang

DOI: https://doi.org/10.1186/s13046-021-01902-0

2021-04-16

Abstract:An amendment to this paper has been published and can be accessed via the original article.

oncology
Correction To: Therapeutic Efficacy, Pharmacokinetic Profiles, and Toxicological Activities of Humanized Antibody-Drug Conjugate Zt/g4-MMAE Targeting RON Receptor Tyrosine Kinase for Cancer Therapy

Hang-Ping Yao,Liang Feng,Sreedhar Reddy Suthe,Ling-Hui Chen,Tian-Hao Weng,Chen-Yu Hu,Eun Sung Jun,Zhi-Gang Wu,Wei-Lin Wang,Song Cheol Kim,Xiang-Min Tong,Ming-Hai Wang

DOI: https://doi.org/10.1186/s40425-019-0571-7

IF: 12.469

2019-01-01

Journal for ImmunoTherapy of Cancer

Abstract:Following publication of the original article [1], the author reported two errors in the authors affiliations:
Erratum: Lycorine hydrochloride inhibits melanoma cell proliferation, migration and invasion via down-regulating p21Cip1/WAF1

Shaomin Shi,Chongyang Li,Yanli Zhang,Chaowei Deng,Mengqin Tan,Guangzhao Pan,Juan Du,Yacong Ji,Qian Li,Hanghua Liang,Wei Liu,Leiyang Guo,Gaichao Zhao,Yaling Liu,Hongjuan Cui

DOI: https://doi.org/10.62347/UGBF6070

2024-09-25

Abstract:[This corrects the article on p. 1391 in vol. 11, PMID: 33948364.].
Correction: Xiang, S., Et Al. Schisandrin B Induces Apoptosis and Cell Cycle Arrest of Gallbladder Cancer Cells. Molecules 2014, 19, 13235–13250

Shan-Shan Xiang,Xu-An Wang,Huai-Feng Li,Yi-Jun Shu,Run-Fa Bao,Fei Zhang,Yang Cao,Yuan-Yuan Ye,Hao Weng,Wen-Guang Wu,Jia-Sheng Mu,Xiang-Song Wu,Mao-Lan Li,Yun-Ping Hu,Lin Jiang,Zhu-Jun Tan,Wei Lu,Feng Liu,Ying-Bin Liu

DOI: https://doi.org/10.3390/molecules21050673

2016-01-01

Abstract:We would like to change the Affiliation addresses on Page 13235 of paper [1], [...]
Correction To: CircDLST Promotes the Tumorigenesis and Metastasis of Gastric Cancer by Sponging Mir-502-5p and Activating the NRAS/MEK1/ERK1/2 Signaling

Jing Zhang,Lidan Hou,Rui Liang,Xiaoyu Chen,Rui Zhang,Wei Chen,Jun Zhu

DOI: https://doi.org/10.1186/s12943-020-01243-0

IF: 37.3

2020-01-01

Molecular Cancer

Abstract:An amendment to this paper has been published and can be accessed via the original article.
Corrigendum to “Suppression of IL-6 Gene by shRNA Augments Gemcitabine Chemosensitization in Pancreatic Adenocarcinoma Cells”

Haibo Xing,Mengting Tong,Jing Wang,Hanqing Hu,Chongya Zhai,Chunhui Huang,Da Li

DOI: https://doi.org/10.1155/2022/9767389

2022-01-01

BioMed Research International

Abstract:[This corrects the article DOI: 10.1155/2018/3195025.].
Correction to: Musashi2 promotes EGF-induced EMT in pancreatic cancer via ZEB1-ERK/MAPK signaling

Weiwei Sheng,Xiaoyang Shi,Yiheng Lin,Jingtong Tang,Chao Jia,Rongxian Cao,Jian Sun,Guosen Wang,Lei Zhou,Ming Dong

DOI: https://doi.org/10.1186/s13046-020-01663-2

2020-08-24

Abstract:An amendment to this paper has been published and can be accessed via the original article.

oncology
Correction: Zheng, L., et al. PBN11-8, a Cytotoxic Polypeptide Purified from Marine Bacillus, Suppresses Invasion and Migration of Human Hepatocellular Carcinoma Cells by Targeting Focal Adhesion Kinase Pathways. Polymers 2018, 10, 1043

Lanhong Zheng,Xiangjie Zhu,Kangli Yang,Meihong Zhu,Ammad Ahmad Farooqi,Daole Kang,Mi Sun,Yixin Xu,Xiukun Lin,Yingang Feng,Fangfang Liang,Fuming Zhang,Robert J. Linhardt,Ammad Farooqi,Robert Linhardt

DOI: https://doi.org/10.3390/polym13010166

IF: 5

2021-01-05

Polymers

Abstract:The authors wish to make a change to the published paper [...]

polymer science
Erratum: Author correction to 'VEGFR2-targeted antibody fused with IFNamut regulates the tumor microenvironment of colorectal cancer and exhibits potent anti-tumor and anti-metastasis activity' [Acta Pharm Sin B 11 (2021) 420-433]

Pengzhao Shang,Rui Gao,Yijia Zhu,Xiaorui Zhang,Yang Wang,Minji Guo,Hui Peng,Min Wang,Juan Zhang

DOI: https://doi.org/10.1016/j.apsb.2024.02.014

Abstract:[This corrects the article DOI: 10.1016/j.apsb.2020.09.008.].
[Corrigendum] PF‐2341066 combined with celecoxib promotes apoptosis and inhibits proliferation in human cholangiocarcinoma QBC939 cells

Chen Chen,Dinghua Yang,Qinghua Zeng,Liang Luo,Chengzhi Cai

DOI: https://doi.org/10.3892/etm.2024.12399

IF: 2.7

2024-01-24

Experimental and Therapeutic Medicine

Abstract:[This corrects the article DOI: 10.3892/etm.2018.5967.].

medicine, research & experimental
Correction: Treating ICB-resistant cancer by inhibiting PD-L1 via DHHC3 degradation induced by cell penetrating peptide-induced chimera conjugates

Yu-Ying Shi,Gang Fan,Ruirong Tan,Shan Li,Hua-Bing Sun,Rui Li,Mengni Yang,Shanshan Gao,Miao Liu,Meng-Yuan Dai

DOI: https://doi.org/10.1038/s41419-024-07182-8

2024-11-24

Cell Death and Disease

Abstract:Cell Death & Disease, Published online: 18 November 2024; doi:10.1038/s41419-024-07182-8 Correction: Treating ICB-resistant cancer by inhibiting PD-L1 via DHHC3 degradation induced by cell penetrating peptide-induced chimera conjugates

cell biology
Correction to: Human drug efflux transporter ABCC5 confers acquired resistance to pemetrexed in breast cancer

Jihui Chen,Zhipeng Wang,Shouhong Gao,Kejin Wu,Fang Bai,Qiqiang Zhang,Hongyu Wang,Qin Ye,Fengjing Xu,Hong Sun,Yunshu Lu,Yan Liu

DOI: https://doi.org/10.1186/s12935-021-01876-1

IF: 6.429

2021-03-25

Cancer Cell International

Abstract:An amendment to this paper has been published and can be accessed via the original article.

oncology
Correction to: The role of microRNA-133b and its target gene FSCN1 in gastric cancer

Lihua Guo,Hua Bai,Dongling Zou,Tao Hong,Jie Liu,Jiaqiang Huang,Pengfei He,Qi Zhou,Jinsheng He

DOI: https://doi.org/10.1186/s13046-020-01716-6

2020-10-20

Abstract:An amendment to this paper has been published and can be accessed via the original article.

oncology
Correction to: Circular RNA circ-ZKSCAN1 inhibits bladder cancer progression through miR-1178-3p/p21 axis and acts as a prognostic factor of recurrence

Junming Bi,Hongwei Liu,Wei Dong,Weibin Xie,Qingqing He,Zijian Cai,Jian Huang,Tianxin Lin

DOI: https://doi.org/10.1186/s12943-020-01265-8

IF: 37.3

2020-10-12

Molecular Cancer

Abstract:An amendment to this paper has been published and can be accessed via the original article.

oncology,biochemistry & molecular biology
[Corrigendum] The cranberry flavonoids PAC DP‑9 and quercetin aglycone induce cytotoxicity and cell cycle arrest and increase cisplatin sensitivity in ovarian cancer cells

Yifei Wang,Alex Han,Eva Chen,Rakesh K Singh,Clinton O Chichester,Richard G Moore,Ajay P Singh,Nicholi Vorsa

DOI: https://doi.org/10.3892/ijo.2022.5408

Abstract:Following the publication of this article, an interested reader drew to the author's attention that, in Fig. 5D on p. 1931, the two rightmost panels appeared to have been inverted for the SKOV3 cell line (i.e., the 'Q‑aglycone' and 'PAC DP‑9' data panels appeared to have been included in this figure the wrong way around). The authors checked the figure, and realized that these panels had indeed erroneously been inverted during the assembly of the figure. The corrected version of Fig. 5 is shown on the next page. The authors regret that this error was not picked up upon before the paper was sent to press, and thank the Editor of International Journal of Oncology for allowing them the opportunity to publish this corrigendum. Furthermore, they regret any inconvenience caused to the readership. [International Journal of Oncology 46: 1924‑1934, 2015; DOI: 10.3892/ijo.2015.2931].
Correction To: MiR-139-5p Inhibits Migration and Invasion of Colorectal Cancer by Downregulating AMFR and NOTCH1

Mingxu Song,Yuan Yin,Jiwei Zhang,Binbin Zhang,Zehua Bian,Chao Quan,Leyuan Zhou,Yaling Hu,Qifeng Wang,Shujuan Ni,Bojian Fei,Weili Wang,Xiang Du,Hua Dong,Zhaohui Huang

DOI: https://doi.org/10.1007/s13238-021-00826-x

2021-01-01

Protein & Cell

Abstract:In the original publication the display of Fig. 1 is incorrect. The correct figure is available in this correction.
Correction: Targeting Tumor Cell-Derived CCL2 As a Strategy to Overcome Bevacizumab Resistance in ETV5+ Colorectal Cancer.

Haoran Feng,Kun Liu,Xiaonan Shen,Juyong Liang,Changgang Wang,Weihua Qiu,Xi Cheng,Ren Zhao

DOI: https://doi.org/10.1038/s41419-020-03208-z

2020-01-01

Abstract:A Correction to this paper has been published: https://doi.org/10.1038/s41419-020-03208-z.
Corrigendum: Anti-cancer immune effect of human colorectal cancer neoantigen peptide based on MHC class I molecular affinity screening

Siyu Zhang,Changxin Huang,Yongqiang Li,Zhaoyang Li,Ying Zhu,Lili Yang,Haokun Hu,Quan Sun,Mengmeng Liu,Songqiang Cao

DOI: https://doi.org/10.3389/fimmu.2024.1514836

IF: 7.3

2024-12-03

Frontiers in Immunology

Abstract:This article is a correction to: Anti-cancer immune effect of human colorectal cancer neoantigen peptide based on MHC class I molecular affinity screening

immunology
Correction: Protein 4.1N acts as a potential tumor suppressor linking PP1 to JNK-c-Jun pathway regulation in NSCLC

Zi Wang,Bianying Ma,Hui Li,Xiaojuan Xiao,Weihua Zhou,Feng Liu,Bin Zhang,M. Zhu,Qin Yang,Yayue Zeng,Yang Sun,Shuming Sun,Yanpeng Wang,Yibin Zhang,Haibo Weng,Lixiang Chen,Mao Ye,X. An,Jing Liu

DOI: https://doi.org/10.18632/oncotarget.27282

2019-01-01

Oncotarget

Abstract:[This corrects the article DOI: 10.18632/oncotarget.6312.].

Correction to: RGD4C peptide mediates anti-p21Ras scFv entry into tumor cells and produces an inhibitory effect on the human colon cancer cell line SW480

RGD4C peptide mediates anti-p21Ras scFv entry into tumor cells and produces an inhibitory effect on the human colon cancer cell line SW480

Correction to: Circ-ASH2L promotes tumor progression by sponging miR-34a to regulate Notch1 in pancreatic ductal adenocarcinoma

Correction To: Therapeutic Efficacy, Pharmacokinetic Profiles, and Toxicological Activities of Humanized Antibody-Drug Conjugate Zt/g4-MMAE Targeting RON Receptor Tyrosine Kinase for Cancer Therapy

Erratum: Lycorine hydrochloride inhibits melanoma cell proliferation, migration and invasion via down-regulating p21Cip1/WAF1

Correction: Xiang, S., Et Al. Schisandrin B Induces Apoptosis and Cell Cycle Arrest of Gallbladder Cancer Cells. Molecules 2014, 19, 13235–13250

Correction To: CircDLST Promotes the Tumorigenesis and Metastasis of Gastric Cancer by Sponging Mir-502-5p and Activating the NRAS/MEK1/ERK1/2 Signaling

Corrigendum to “Suppression of IL-6 Gene by shRNA Augments Gemcitabine Chemosensitization in Pancreatic Adenocarcinoma Cells”

Correction to: Musashi2 promotes EGF-induced EMT in pancreatic cancer via ZEB1-ERK/MAPK signaling

Correction: Zheng, L., et al. PBN11-8, a Cytotoxic Polypeptide Purified from Marine Bacillus, Suppresses Invasion and Migration of Human Hepatocellular Carcinoma Cells by Targeting Focal Adhesion Kinase Pathways. Polymers 2018, 10, 1043

Erratum: Author correction to 'VEGFR2-targeted antibody fused with IFNamut regulates the tumor microenvironment of colorectal cancer and exhibits potent anti-tumor and anti-metastasis activity' [Acta Pharm Sin B 11 (2021) 420-433]

[Corrigendum] PF‐2341066 combined with celecoxib promotes apoptosis and inhibits proliferation in human cholangiocarcinoma QBC939 cells

Correction: Treating ICB-resistant cancer by inhibiting PD-L1 via DHHC3 degradation induced by cell penetrating peptide-induced chimera conjugates

Correction to: Human drug efflux transporter ABCC5 confers acquired resistance to pemetrexed in breast cancer

Correction to: The role of microRNA-133b and its target gene FSCN1 in gastric cancer

Correction to: Circular RNA circ-ZKSCAN1 inhibits bladder cancer progression through miR-1178-3p/p21 axis and acts as a prognostic factor of recurrence

[Corrigendum] The cranberry flavonoids PAC DP‑9 and quercetin aglycone induce cytotoxicity and cell cycle arrest and increase cisplatin sensitivity in ovarian cancer cells

Correction To: MiR-139-5p Inhibits Migration and Invasion of Colorectal Cancer by Downregulating AMFR and NOTCH1

Correction: Targeting Tumor Cell-Derived CCL2 As a Strategy to Overcome Bevacizumab Resistance in ETV5+ Colorectal Cancer.

Corrigendum: Anti-cancer immune effect of human colorectal cancer neoantigen peptide based on MHC class I molecular affinity screening

Correction: Protein 4.1N acts as a potential tumor suppressor linking PP1 to JNK-c-Jun pathway regulation in NSCLC